BioXcel Therapeutics (BTAI) Accumulated Depreciation (2017 - 2026)

BioXcel Therapeutics' Accumulated Depreciation history runs 10 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 17.87% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 17.87% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 19.97% from the prior year.
• Accumulated Depreciation grew to $1.9 million in Q1 2026 per BTAI's latest filing, from $1.8 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $1.9 million in Q1 2026 and bottomed at $679000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $1.3 million (2024), against an average of $1.3 million.
• Across the five-year window, Accumulated Depreciation soared 61.22% in 2022 and grew 17.87% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $885000.0 in 2022, then soared by 34.8% to $1.2 million in 2023, then advanced by 25.9% to $1.5 million in 2024, then increased by 19.97% to $1.8 million in 2025, then climbed by 3.22% to $1.9 million in 2026.
• Per Business Quant, the three latest BTAI Accumulated Depreciation figures stand at $1.9 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025).